Accessibility Menu
NextCure Stock Quote

NextCure (NASDAQ: NXTC)

$11.79
(9.0%)
+0.97
Price as of October 21, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$11.79
Daily Change
(9.0%) +$0.97
Day's Range
$10.51 - $12.25
Previous Close
$11.79
Open
$10.59
Beta
0.73
Volume
85,903
Average Volume
121,422
Market Cap
29M
Market Cap / Employee
$10.82M
52wk Range
$2.69 - $19.2
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$25.91
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

NextCure Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
NXTC-26.68%-91.46%-38.86%-95%
S&P+14.84%+96.04%+14.41%+135%

NextCure Company Info

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.63M9.7%
Market Cap$12.90M-70.9%
Market Cap / Employee$0.30M0.0%
Employees43-47.6%
Net Income-$26.81M-74.0%
EBITDA-$26.66M-68.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$4.89M-76.5%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$4.67M-16.5%
Short Term Debt$0.64M12.5%

Ratios

Q2 2025YOY Change
Return On Assets-81.09%-33.2%
Return On Invested Capital-43.19%-13.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$22.71M-125.4%
Operating Free Cash Flow-$22.71M-132.3%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.510.330.240.41-8.98%
Price to Tangible Book Value5.383.422.472.77-48.51%
Enterprise Value to EBITDA2.653.493.330.63-72.04%
Return on Equity-57.9%-61.9%-63.9%-104.1%90.10%
Total Debt$5.67M$5.95M$5.84M$5.31M-13.85%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.